AQR Capital Management LLC Has $37.86 Million Stake in Penumbra, Inc. (NYSE:PEN)

AQR Capital Management LLC lifted its holdings in Penumbra, Inc. (NYSE:PEN - Free Report) by 19.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,435 shares of the company's stock after acquiring an additional 26,144 shares during the quarter. AQR Capital Management LLC owned approximately 0.42% of Penumbra worth $37,863,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Quadrant Capital Group LLC grew its holdings in shares of Penumbra by 6.6% during the fourth quarter. Quadrant Capital Group LLC now owns 632 shares of the company's stock worth $150,000 after purchasing an additional 39 shares during the last quarter. Pallas Capital Advisors LLC lifted its position in Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after buying an additional 41 shares in the last quarter. Pacer Advisors Inc. grew its holdings in Penumbra by 1.0% during the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company's stock worth $1,359,000 after acquiring an additional 57 shares during the last quarter. CIBC Asset Management Inc increased its position in Penumbra by 5.4% in the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company's stock valued at $281,000 after acquiring an additional 61 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in shares of Penumbra by 3.7% in the fourth quarter. Corient Private Wealth LLC now owns 1,695 shares of the company's stock worth $403,000 after acquiring an additional 61 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Penumbra Trading Up 1.4 %

Shares of NYSE:PEN opened at $295.97 on Friday. The firm has a market cap of $11.46 billion, a price-to-earnings ratio of 870.50, a PEG ratio of 2.83 and a beta of 0.56. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company's fifty day simple moving average is $277.12 and its 200 day simple moving average is $257.58. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. The company had revenue of $324.14 million for the quarter, compared to analyst estimates of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's quarterly revenue was up 16.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.41 earnings per share. As a group, research analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PEN. Wells Fargo & Company raised their price target on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Robert W. Baird boosted their target price on Penumbra from $316.00 to $325.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Bank of America initiated coverage on Penumbra in a report on Friday, March 14th. They issued a "buy" rating and a $320.00 price target on the stock. BTIG Research reissued a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Finally, StockNews.com upgraded shares of Penumbra from a "hold" rating to a "buy" rating in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Penumbra currently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Insiders Place Their Bets

In other news, Director Thomas Wilder sold 360 shares of the company's stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $264.58, for a total value of $95,248.80. Following the sale, the director now directly owns 4,533 shares of the company's stock, valued at approximately $1,199,341.14. This represents a 7.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Adam Elsesser sold 61,600 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the completion of the sale, the chief executive officer now owns 16,376 shares of the company's stock, valued at $4,644,069.84. This trade represents a 79.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,446 shares of company stock valued at $39,543,953 in the last three months. 5.00% of the stock is currently owned by corporate insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.